Elsevier

Biochemical Pharmacology

Volume 46, Issue 9, 2 November 1993, Pages 1637-1652
Biochemical Pharmacology

7-S-Glutathionyl-tryptamine-4,5-dione: A possible aberrant metabolite of serotonin

https://doi.org/10.1016/0006-2952(93)90334-SGet rights and content

Abstract

Tryptamine-4,5-dione (Compound 1) is an in vitro oxidation product of 5-hydroxytryptamine (5-HT). Recent evidence has suggested that aberrant oxidations of 5-HT occur in the central nervous system of individuals with Alzheimer's disease (AD). In the event that Compound 1 is formed as a result of oxidation of 5-HT within serotonergic nerve terminals or axons, it would be expected to be rapidly conjugated by intraneuronal glutathione (GSH) to give 7-5-glutathionyl-tryptamine-4,5-dione (Compound 2). When injected into the brains of laboratory mice, Compound 2 was lethal (LD50 = 21 μg) and evoked hyperactivity for the first 30 min following drug administration. Particularly during this hyperactive phase Compound 2 caused a statistically significant decrease in whole brain levels of norepinephrine and 5-HT. Levels of dopamine were also decreased while whole brain concentrations of its metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, were increased significantly. In the presence of GSH, NADPH and ascorbic acid. Compound 2 redox cycled in reactions that catalyzed the oxidation of these cellular reductants by molecular oxygen and formed H2O2 as a byproduct. Compound 2 also reacted with molar excesses of GSH to form more structurally complex glutathionyl conjugates. Several of these conjugates have been isolated and their structures determined using spectroscopic methods. It is conceivable that one or more of these conjugates might serve as analytical markers in a search for evidence in support of the hypothesis that aberrant oxidations of 5-HT occur in the Alzheimer brain. The redox cycling properties of Compound 2 and its facile reactions with cellular nucleophiles such as GSH may represent mechanisms that contribute to the toxicity of this drug.

References (44)

  • JL Owens et al.

    Electrochemical oxidation of uric acid and xanthine. An investigation by cyclic voltammetry, double potential step chronoamperometry and thin-layer spe

    J Electronal Chem Interfacial Electrochem

    (1978)
  • C Eva et al.

    Acetylcholine measurements by high performance liquid chromatography using an enzyme-loaded postcolumn reactor

    Anal Biochem

    (1984)
  • DM Frank et al.

    Model study on the bioreduction of paraquat, MPP+, and analogs. Evidence against a “redox cycling” mechanism in MPTP neurotoxicitv

    Biochem Biophys Res Commun

    (1987)
  • DJ Miner et al.

    Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism

    Biochem Pharmacol

    (1979)
  • DT Sawyer et al.

    The chemistry of Superoxide ion

    Tetrahedron

    (1979)
  • SP Raps et al.

    Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons

    Brain Res

    (1989)
  • H Kappus

    Overview of enzyme systems involved in bioreduction of drugs and redox cycling

    Bio-chem Pharmacol

    (1986)
  • MA Trush et al.

    Activation of pharmacologic agents to radical intermediates. Implications for the role of free radicals in drug action and toxicity

    Biochem Pharmacol

    (1982)
  • DM Bowen et al.

    Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease

    J Neurochem

    (1983)
  • RJ D'Amato et al.

    Aminergic systems in Alzheimer's disease and Parkinson's disease

    Ann Neurol

    (1987)
  • DMA Mann et al.

    Neurotransmitter deficit in Alzheimer's disease and other dementing disorders

    Hum Neurobiol

    (1986)
  • AM Palmer et al.

    Presynaptic serotonergic dysfunction in patients with Alzheimer's disease

    J Neurochem

    (1987)
  • Cited by (0)

    View full text